# Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC

> **NCT07385664** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ji Yongling** · enrollment: 66 (estimated)

## Conditions studied

- Resectable Esophageal Cancer

## Interventions

- **COMBINATION_PRODUCT:** Neoadjuvant Chemoimmunotherapy or Concurrent Chemoradiotherapy

## Key facts

- **NCT ID:** NCT07385664
- **Lead sponsor:** Ji Yongling
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-28
- **Primary completion:** 2027-01-30
- **Final completion:** 2028-02-01
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07385664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07385664, "Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07385664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*